HER2/Neu is overexpressed in 25 ± 30% of all human breast cancers as a result of both gene ampli®cation and enhanced transcription. Transcriptional upregulation of HER2/neu leads to a 6 ± 8-fold increased abundance of its mRNA per gene copy and likely results from the elevated activity of transcription factors acting on the HER2/neu promoter. Here we report that transcripts of PEA3, an ETS transcription factor implicated in oncogenesis, were increased in 93% of HER2/Neuoverexpressing human breast tumor samples. Analyses to uncover the molecular basis for elevated PEA3 transcripts in HER2/Neu-positive breast tumors revealed that the HER2/Neu receptor tyrosine kinase initiated an intracellular signaling cascade resulting in increased PEA3 transcriptional activity; transcriptionally-activated PEA3 stimulated HER2/neu and PEA3 gene transcription by binding to sites in the promoters of these genes. PEA3 also activates transcription of genes encoding matrix-degrading proteinases, enzymes required for tumor cell migration and invasion. These ®ndings implicate PEA3 in the initiation and progression of HER2/Neu positive breast cancer, and suggest that PEA3 and signaling proteins aecting its regulation are appropriate therapeutic targets.
Introduction
The HER2/neu proto-oncogene encodes a 185 kDa receptor tyrosine kinase structurally related to the epidermal growth factor receptor (c-ErbB-1) (Singleton and Strickler, 1992) . Overexpression of the human HER2/neu gene is implicated in the genesis of a number of human tumors including 20 ± 30% of all breast carcinomas, and is linked to an increased propensity of tumors to invade and metastasize resulting in a poor prognosis for the patient (Singleton and Strickler, 1992; Tripathy and Benz, 1994) . Upregulation of HER2/Neu protein expression in breast tumors also is correlated with a poor response to hormonal and chemotherapeutic agents (Muss et al., 1994; Wright et al., 1992; Benz et al., 1992) . At least 40% of all non-invasive intraductal breast carcinomas (ductal carcinomas in situ, DCIS) overexpress HER2/ Neu suggesting that this event occurs early during breast tumorigenesis (Liu et al., 1992) .
Ampli®cation of the HER2/neu gene accounts in part for the increased expression of the HER2/Neu protein in breast tumor cells (Slamon et al., 1987) . However, an additional mechanism is likely at play because human breast tumor-derived cell lines overexpress HER2/Neu mRNA 6 ± 8-fold per gene copy compared to normal mammary cell lines independent of the state of HER2/neu gene ampli®cation (King et al., 1989; Inglehart et al., 1990; Parkes et al., 1990) . Deregulated HER2/Neu mRNA accumulation results from an increased rate of transcription of the gene (Hollywood and Hurst, 1993) and not from an increase in the half-life of the HER2/Neu mRNA (Pasleau et al., 1993) . Analyses of HER2/neu promoter activity in human breast tumor cell lines that express varying amounts of HER2/Neu suggets that its upregulation may be due to the increased abundance and activity of AP-2 family members (Hollywood and Hurst, 1993; Bosher et al., 1995 Bosher et al., , 1996 and those of the Ets family of transcriptional regulatory proteins (Scott et al., 1994) such as PEA3 (polyomavirus enhancer activator 3) (Xin et al., 1992) .
PEA3 is the founding member of a subfamily of ets genes that include ER81 (Brown and McKnight, 1992) and ERM (Monte et al., 1994) . All Ets proteins contain an evolutionarily-conserved, *85 amino acid ETS DNA binding domain (Karim et al., 1990) ; subfamily members possess nearly identical ETS domains and share additional regions of sequence similarity (Macleod et al., 1992) . Ets proteins bind to related *10 base pair DNA sequence elements in the promoters of target genes where they act to regulate transcription (Macleod et al., 1990; Seth et al., 1992; Wasylyk et al., 1993) . Many candidate PEA3 target genes have been reported (Macleod et al., 1990; Seth et al., 1992; Wasylyk et al., 1993) . A signi®cant fraction of these encode proteinases required for degradation of the extracellular matrix. The unregulated expression of these enzymes has been associated with the propensity of tumor cells to metastasize (Kohn and Liotta, 1995) . For example, PEA3 binding sites occur in the promoters of the serine proteinase urokinase-type plasminogen activator (Rorth et al., 1990; Nerlov et al., 1992) as well as the matrix metalloproteinases (MMP) gelatinase B (92 kDa type IV collagenase or MMP-9), interstitial collagenase (MMP-1), stromelysin-1 (transin or MMP-3), stromelysin-2 (MMP-10), stromelysin-3 (MMP-11) and matrilysin (pump-1 or MMP-7) (Matrisian, 1994; Higashino et al., 1995) . PEA3 directly activates transcription from the MMP-1, MMP-9 and MMP-11 promoters (Higashino et al., 1995) . In agreement with these ®ndings, forced expression of PEA3 in the non-metastatic MCF-7 human breast cancer cell line increases its invasive and metastatic properties (Kaya et al., 1996) . Hence PEA3 may be a key regulator of the invasive and metastatic phenotype.
Chromosomal translocations involving the PEA3 gene have been implicated in sarcomas in humans (Kaneko et al., 1996) . A segment of the EWS gene is translocated to the PEA3 gene (also known as E1A-F) in an undierentiated sarcoma (Kaneko et al., 1996) and extraosseous Ewing's sarcoma (Urano et al., 1996) . The same segment of EWS is translocated and juxtaposed to sequences encoding the ETS domain of other ets genes (Delattre et al., 1992; Zucman et al., 1993; Sorensen et al., 1994; Jeon et al., 1995) . Commonly the products of such chimeric genes encode EWS-Ets fusion proteins with increased transcriptional activity (Bailly et al., 1994; Lessnick et al., 1995) .
Overexpression of the PEA3 gene occurs in mammary tumors of transgenic mice engineered to express the rat HER2/neu gene in their mammary epithelium (Trimble et al., 1993) . In this experimental system HER2/neu induces metastatic mammary tumors thereby closely mimicking the human disease (Dankort et al., 1996) . All primary and metastatic mammary tumors of these transgenic mice overexpress PEA3 mRNA, whereas normal tissues adjacent to the primary tumor or metastases do not (Trimble et al., 1993) . HER2/neu transcripts from the endogenous mouse gene also are elevated in the PEA3-expressing mammary tumors (Trimble et al., 1993) . To account for these observations we postulated that an unknown initiating event results in enhanced HER2/Neu tyrosine kinase activity, which stimulates the activity of low basal levels of PEA3 protein present in the mammary epithelium (Trimble et al., 1993 ). Transcriptionallyactivated PEA3 then increases its own expression as well as that of the endogenous HER2/neu gene establising an autostimulatory oncogenic loop. Increased PEA3 protein levels could lead to elevated matrix-degrading proteinase gene transcription thereby conferring invasive and metastatic properties to the tumor cells.
The involvement of ets genes in human breast cancer is largely unexplored. The fact that the PEA3 gene is overexpressed in mouse models of this disease led us to examine a potential link between PEA3 and HER2/Neu overexpression in human breast cancer. To this end we measured PEA3 RNA levels in an archived panel of non-invasive DCIS and invasive ductal carcinomas with known HER2/Neu receptor tyrosine kinase status. Increased amounts of PEA3 RNA were detected in 490% of HER2/Neu-positive breast tumors. Transient transfection studies in cell lines revealed that HER2/Neu increased the transcriptional activity of the PEA3 protein, and that together HER2/Neu and PEA3 synergized to augment transcription of the HER2/neu and PEA3 genes. These ®ndings suggest a molecular mechanism whereby genetic alterations aecting the tyrosine kinase activity of HER2/Neu lead to human breast cancer.
Results
Upregulation of PEA3 expression in HER2/Neu-positive human breast tumors
The lack of suitable antibodies to study PEA3 protein expression in paran-embedded surgical samples of human tissues by immunocytochemistry dictated that we measure PEA3 RNA in breast tumor samples by in situ hybridization with labeled riboprobes. In addition to normal breast tissue samples (n=5), 74 primary breast tumors of known HER2/Neu receptor status (determined immunohistochemically as described in Materials and methods) were analysed, including 41 non-invasive DCIS breast tumors and 33 invasive ductal breast carcinomas. Figure 1a and b, and d and e are not immediate consecutive sections and hence do not appear morphologically identical. In general minimum background PEA3 hybridization (equivalent to that obtained with the sense probe) was detected in the tumor's non-epithelial stromal components; a twofold increase over background PEA3 signal was observed in some stromal areas containing heavy lymphocytic in®ltrates (data not shown). Normal mammary epithelial tissue (ducts and lobular units), both in separate samples (n=6) and in areas of the tumor samples distant from the neoplastic epithelium, showed background levels of PEA3 RNA, indicating low or undetectable levels of PEA3 expression (data not shown).
By contrast to the lack of PEA3 overexpression in normal breast tissue, PEA3 overexpression was common in the 74 breast tumors including both non-invasive (n=41) and invasive tumor samples (n=33). Table 1 summarizes these PEA3 results in relationship to the HER2/Neu status of the tumors. Ninety-three percent of all HER2/Neu-positive tumors overexpressed PEA3 (P50.01). Less than half of the HER2/Neu-negative tumors, whether invasive or not, overexpressed PEA3. The statistically signi®cant association between PEA3 and HER2/Neu overexpression was not found in these same samples with another epithelial-restricted Ets family member, Ets-2. Ets-2 was overexpressed in 35% of noninvasive and in 57% of invasive breast tumors in comparable fractions of HER2/Neu-positive and HER2/Neu-negative tumors (Table 1) . PEA3-positiv-ity did not associate with known prognostic markers for invasive breast tumors (Benz et al., 1995) including nuclear grade, estrogen receptor (ER) status and S-phase fraction (Table 1) .
HER2/Neu stimulates PEA3-dependent gene expression
We have suggested that increased PEA3 mRNA in HER2/Neu-expressing mouse mammary tumors results initially from stimulation of the transcriptional activity of PEA3 by the HER2/Neu receptor tyrosine kinase (Trimble et al., 1993) . To learn whether the activity of PEA3 is indeed regulated by HER2/Neu, we enquired whether coexpression of HER2/Neu and PEA3 in the same cells led to increased PEA3-dependent reporter gene expression. To this end we cotransfected monkey COS cells with a PEA3 reporter plasmid encoding chloramphenicol acetyl transferase (CAT), and eector plasmids encoding mouse (m) PEA3 and, either the wild type (wt) rat HER2/Neu receptor tyrosine kinase, or the oncogenically-activated version thereof (activated HER2/Neu). The arti®cial promoter of the PEA3 reporter comprises four head-to-tail copies of the PEA3 element located immediately upstream of a synthetic TATA box (Xin et al., 1992) . The PEA3 and rat HER2/Neu eector plasmids encode these proteins under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) and the Moloney murine leukemia virus LTR respectively (Morgenstern and Land, 1990) . Generally ectopic expression of PEA3 from the PEA3 eector plasmid increases CAT synthesis from the reporter by 5 ± 10-fold dependent on the presence of a functional PEA3 elements in the promoter of the reporter (Xin et al., 1992) .
To measure an eect of HER2/Neu on PEA3-dependent gene expression we used a concentration of the PEA3 eector that led to an increase in CAT expression from the reporter of about threefold greater than that eected by endogenous factors in COS cells (Figure 2a compare lanes 1 and 2) . Simultaneous transfection of the reporter with the eector encoding wt HER2/Neu did not aect CAT expression suggesting that the activity of endogenous factors functioning through the arti®cial promoter were unaected by wt HER2/Neu (compare lanes 1 and 3). By contrast, cotransfection of the reporter with both the PEA3 and HER2/Neu eectors led to an *®vefold increase in CAT expression representing about a twofold increase in PEA3-dependent CAT expression (twofold greater than that eected by PEA3 alone) (compare lanes 2 and 4). Cotransfection of the reporter with the eector encoding constitutivelyactivated HER2/Neu increased CAT expression mediated by the endogenous activity about 1.5-fold (lane 5). Together PEA3 and HER2/Neu increased CAT expression 11-fold above that of the endogenous level representing a fourfold increase in PEA3-dependent reporter gene expression (compare lanes 2 and 6). Hence both wt and activated HER2/Neu stimulated PEA3-dependent CAT expression, albeit to diering extents.
To determine whether the wt and constitutivelyactivated HER2/Neu proteins were expressed at similar levels following transfection, we used a HER2/Neuspeci®c antiserum and Western immunoblotting with the same lysates that were used for the CAT assays. A representative immunoblot is depicted in Figure 2b . COS cells express endogenous HER2/Neu (lane 1); the amount of this protein was not appreciably increased after transfection of the PEA3 eector (compare lanes 1 and 2). Both the wt and constitutively-activated HER2/Neu proteins were overproduced to similar extents in COS cells transfected with the HER2/Neu eectors (compare lane 1 to lanes 3 and 5). Cotransfection of the PEA3 and HER2/Neu expression vectors did not appreciably alter the amount of HER2/Neu synthesized in COS cells (compare lanes 3 and 5 to lanes 4 and 6). Hence increased PEA3-dependent CAT gene expression following cotransfection of the PEA3 and HER2/Neu eectors did not result from changes in the amount of HER2/Neu. Furthermore, the dierence in the capacity of the wt and activated HER2/Neu proteins to increase PEA3-dependent gene expression was not due to dierences in the abundance of the two proteins in the transfected cells. Rather we suspect that the higher intrinsic receptor tyrosine activity of the activated HER2/Neu protein (Hynes and Stern, 1994) accounts for its increased capacity to stimulate PEA3-dependent reporter gene expression by comparison to its wt counterpart.
We also monitored the abundance of the PEA3 protein following transfection with the various eectors (7) 13 (46) 15 ( 
PEA3 bind to multiple sites within the PEA3 promoter
We previously hypothesized that the increased amounts of PEA3 mRNA in HER2/Neu-induced mouse mammary tumors results in part from the ability of PEA3 to regulate its own transcription by binding to sites within the PEA3 promoter. To examine the latter possibility we cloned and sequenced the mouse (m) PEA3 gene including 3 kb of the 5' non-coding region (Laing, Barrett, Xin, Smillie and Hassell, in preparation). Promoter mapping studies showed that noncoding sequences between 7156 and +676 relative to the 5'-most start site for transcription (+1) were sucient to eect maximal reporter gene expression in the FM3A mouse mammary tumor cell line (Barrett and Hassell, in preparation), which expresses high levels of PEA3 mRNA and protein (Xin et al., 1993) . This region includes 5' non-transcribed sequences, the ®rst non-coding exon, and part of the second coding exon up to but not including the PEA3 translation initiation codon. Inspection of this sequence revealed the occurrence of several candidate PEA3 binding sites between 7355 and +1. To determine whether PEA3 could bind to these sites we employed DNaseI footprinting with an uniquely end-labeled DNA fragment spanning 7355 to +1 of the mPEA3 gene and several sources of PEA3. The latter included recombinant human (h) PEA3 puri®ed from Escherichiae coli, as well as nuclear extracts from two human breast tumor cell lines: MCF-7 cells, which contain relatively little PEA3; and MDA-MB-453 cells, which express comparatively more PEA3 (Scott et al., 1994) . The binding of Ets family proteins to their recognition sequence eects a structural change in DNA that can be detected as a DNaseI hypersensitive site within the central core (5'-GGA, A/T-3') of Ets binding sites (13). Each source of PEA3 induced such a DNaseI hypersensitive sites in the region between 749 and 727 (5'-AAGGAAATG-3') ( Figure 3a) , and between 7302 and 7280 (5'-ACGGAAGC-3') ( Figure 3b ). Because the nuclear extracts from MDA-453 and MCF-7 cells contain a heterogeneous mixture of DNA binding activities as well as diering amounts of PEA3, the DNaseI digestion patterns observed with each extract were somewhat dierent from each other and did not mimic precisely those obtained after use of recombinant PEA3. Titration of the ability of recombinant hPEA3 to protect this DNA fragment from DNaseI digestion revealed that the DNaseI hypersensitive site was unaected by increasing hPEA3 concentration. By contrast, the protected regions expand to include sequences¯anking the PEA3 responsive elements in the PEA3 promoter (data not shown).
PEA3 transactivates the PEA3 promoter
The occurrence of bona ®de PEA3 binding sites in the mPEA3 promoter encouraged us to determine whether PEA3 was capable of regulating its own transcription. We used a reporter comprising 832 base pairs (bp) of the mPEA3 promoter (7156/+676) placed upstream of the luciferase gene and accompanying SV40 transcription termination/polyadenylation signals. This reporter was cotransfected with the PEA3 eector into COS cells. Cotransfection of increasing amounts of the PEA3 eector plasmid with a constant amount of the reporter lead to a dose-dependent increase in luciferase expression (Figure 4a ). This was accompanied by an increase in PEA3 protein synthesis from the PEA3 eector (Figure 4b ). The occurrence of PEA3 binding sites in the PEA3 promoter coupled with the ability of the PEA3 protein to transactivate this promoter strongly suggests that PEA3 is capable of regulating its own synthesis at the transcriptional level.
We have shown in separate experiments that constitutively-activated HER2/Neu stimulated the transcriptional activity of PEA3, and that PEA3 transactivated the PEA3 promoter. To learn whether we could demonstrate both processes in the same experiment, thereby presumably recapitulating the in vivo situation in breast tumors, we cotransfected expression vectors encoding PEA3 and constitutivelyactivated HER2/Neu together with the PEA3 promoter-luciferase reporter into COS cells. Cotransfection of the PEA3 eector with this reporter led to a threefold increase in luciferase expression (Figure 5a compare  lanes 1 and 2) . Cotransfection of the HER2/Neu eector with the same reporter also increased luciferase expression threefold (compare lanes 1 and 3). This suggests that constitutively-activated HER2/ Neu augmented the activity and/or abundance of 1 and 2, and lanes 3 and 4) . Furthermore, HER2/Neu expressed from the eector did not aect the abundance of either endogenous PEA3 (Figure 5c compare lanes 1 and 3) or that encoded by the PEA3 eector (compare lanes 2 and 4). Hence in this experimental setting PEA3 transactivated the PEA3 promoter and this was further augmented by HER2/Neu.
PEA3 regulates HER2/Neu promoter activity
We previously observed that mouse mammary tumors not only overexpress PEA3 RNA but also HER2/neu transcripts derived from the endogenous mouse gene (Trimble et al., 1993) . This and the occurrence of candidate PEA3 binding sites in the HER2/neu upstream region suggested that PEA3 might directly regulate HER2/neu gene transcription in mammary epithelial cells (Hudson et al., 1990; Scott et al., 1994) . To address this we tested the capacity of PEA3 to stimulate CAT expression from a reporter bearing the human HER2/neu promoter. The minimal HER2/neu promoter comprises 500 bp and contains a single PEA3 binding site (Scott et al., 1994) . Cotransfection of cells with increasing amounts of the PEA3 eector and a ®xed amount of this HER2/neu promoter-CAT reporter led to an increase in CAT expression ( Figure  6a compare lanes 1 ± 4). A maximum *®vefold stimulation of CAT activity was achieved by ectopic expression of PEA3 (lane 3). As observed previously, increased PEA3 synthesis accompanied increased CAT expression (data not shown).
To learn whether the PEA3 binding site in the HER2/neu promoter was required for this PEA3-dependent increase in CAT activity we used an altered reporter bearing a mutation in the PEA3 element that prevents PEA3 binding to this site (Scott et al., 1994) . This mutation reduced the basal activity of the HER2/neu promoter in COS cells to values 70% of the control (lane 5). The capacity of the reporter to be transactivated by PEA3 was also reduced to 35% of the control (compare lanes 3 and 6). That the reporter was transactivated at all by PEA3 likely re¯ects the occurrence of weak PEA3 binding sites in the promoter, which may be bound by PEA3 when it is overexpressed. These observations suggest that PEA3 is capable of regulating HER2/neu promoter activity.
The HER2/neu promoter is regulated by mitogens acting through the Ras signal transduction pathway (Hudson et al., 1990) . Activation of this signaling To determine whether the amount PEA3 was increased in the cells transfected with the PEA3 eector, and to learn whether coexpression of HER2/ Neu and PEA3 altered the abundance of PEA3, we assayed the amount of PEA3 in the cells under the various conditions ( Figure 6d ). As expected, endogenous simian PEA3 could not be detected in the COS cells (lane 1); transfection of these cells with the PEA3 eector led to increased PEA3 synthesis (lane 2). We did not detect a change in the amount of endogenous PEA3 following overexpression of HER2/Neu in the transfected COS cells (lane 3). Furthermore, cotransfection of the eector encoding HER2/Neu with that encoding PEA3 did not alter the amount of PEA3 expressed in cells (compare lane 3 and 4). These ®ndings illustrate with the HER2/neu promoter that the eect of HER2/Neu was to increase PEA3 transcriptional activity as measured by PEA3-dependent CAT expression.
Discussion
Our previous observation of increased PEA3 transcripts in HER2/neu-induced mouse mammary tumors (Trimble et al., 1993) has now been extended to human breast tumors. Analysis of 74 human breast tumors (41 DCIS cases and 33 invasive ductal carcinomas) showed that PEA3-positivity was signi®cantly associated with HER2/neu gene overexpression (P50.01). PEA3 expression, which was undetectable in normal breast epithelial tissue, was upregulated in less than half (46%) of HER2/Neu-negative tumors (n=28), but nearly all (93%) HER2/Neu-positive tumors (n=46). In this latter subset, in situ detection of both markers revealed that increased PEA3 transcripts were restricted to the epithelial tumor component that overexpressed HER2/Neu. We did not detect any signi®cant correlation between PEA3 overexpression and other tumor parameters including S-phase fraction, nuclear grade and estrogen receptor status. However, other HER2/Neu-related growth factor receptors (e.g. c-erbB-1 or c-erbB-3), known to be overexpressed in a signi®cant fraction of breast tumors, were not measured and might account for the increased PEA3 transcripts observed in HER2/Neu-negative breast tumors (Tripathy and Benz, 1994) . In this regard it is noteworthy that potential PEA3 binding sites occur in the upstream regulatory regions of both the c-erbB-1 and c-erbB-3 genes. This speci®city of the observed association between overexpression of HER2/Neu and PEA3 is suggested by the fact that upregulation of another Ets family member, Ets-2, was not associated with HER2/Neu positivity. From this survey of selected DCIS and invasive human breast tumors, we conclude that, like increased expression of HER2/Neu, overexpression of PEA3 is an early event in the genesis of human breast cancer and may be linked to increased HER2/Neu receptor tyrosine activity.
Constitutively-activated HER2/Neu stimulated PEA3 transcriptional activity using three dierent promoter-reporter constructs. Each of the promoters contained one or more PEA3 binding sites. The magnitude of this eect varied between four and tenfold depending on the promoter construct used. wt HER2/Neu also increased PEA3 transcriptional activity, albeit to a lesser extent than that eected by constitutively-activated HER2/Neu. This is consistent with the fact that the constitutively-activated HER2/ neu allele encodes a more active receptor tyrosine kinase with increased capacity for mitogenic signaling (Hynes and Stern, 1994) .
The mechanism whereby the transcriptional activity of PEA3 was increased by HER2/Neu is not fully understood. We have reported that Ras stimulates the transcriptional activity of PEA3 by activation of two distinct mitogen-activated protein kinase (MAPK) cascades; the extracellular-regulated kinase (ERK) and the stress-activated protein kinase or Jun kinase (SAPK or JNK) modules (O'Hagan et al., 1996) . HER2/Neu is thought to signal in part through the Ras signal transduction pathway (Hynes and Stern, 1994) . Moreover, HER2/Neu also is able to activate members of the ERK and SAPK/JNK MAPK subfamilies (Ben-Levy et al., 1994) . Hence it seems likely that HER2/Neu regulates PEA3 activity through these MAPK cascades. Whether PEA3, like other Ets proteins (Hill and Treisman, 1995; Cahill et al., 1996; Yang et al., 1996; Janknecht, 1996; Galang et al., 1996) , is directly phosphorylated by MAPKs resulting in an increase in its activity remains unknown. PEA3 contains eight candidate MAPK phosphorylation sites lying outside of its ETS DNA-binding domain (O'Hagan et al., 1996) , it is a phosphoprotein (O'Hagan et al., 1996) , and recombinant PEA3 can be phosphorylated eciently in vitro by both ERK2 and SAPK alpha and beta at serines that are phosphorylated in vivo (Cox, Tozer and Hassell, unpublished) . Experiments are in progress to determine whether PEA3 is a direct downstream target of MAPKs in vivo.
PEA3 bound to the PEA3 promoter in vitro and increased expression of the PEA3 promoter-luciferase reporter construct in vivo. These ®ndings suggest that PEA3 may regulate its own transcription. This, coupled with the observation that HER2/Neu stimulated the activity of PEA3, implies that provided HER2/Neu is active, PEA3 transcripts and protein will accumulate by a positive transcriptional feedback loop. HER2/Neu also increased utilization of the PEA3 promoter in COS cells, which express little or no PEA3. It seems unlikely that another Ets protein mediated this eect because HER2/Neu did not markedly stimulate CAT expression from the arti®cial PEA3-responsive promoter in these same cells. This observation raises the possibility that HER2/Neu upregulates PEA3 gene transcription by increasing PEA3 activity as well as that of other transcription factors acting on the PEA3 promoter. We are currently mapping the HER-2/Neu responsive elements in the PEA3 promoter; knowledge of their sequence may allow us to infer the nature of the trans-acting factors that mediate this eect of HER-2/Neu. PEA3 stimulated expression of a reporter bearing the human HER2/neu promoter contingent on the occurrence of a PEA3 binding site in this promoter. This ®nding lends credence to the hypothesis that increased HER2/Neu receptor tyrosine kinase activity in breast tumors increases PEA3 activity, which could in turn activate HER2/neu transcription. This may account in part for the increased abundance of HER2/ neu transcripts per gene copy found in mouse (Trimble et al., 1993) and human mammary tumors (King et al., 1989; Iglehart et al., 1990; Parkes et al., 1990; Hollywood and Hurst, 1993; Pasleau et al., 1993) . These ®ndings also imply that interference with PEA3 function may reverse the transformed phenotype induced by activated or overexpressed HER2/Neu. In this regard it is noteworthy that dominant-negative mutants of Ets1 and Ets2, which likely function to abrogate transcription of the target genes of many dierent Ets proteins, inhibit transformation of NIH3T3 cells by constitutively-activated HER2/Neu (Galang et al., 1996) . Therefore, therapeutic agents that inhibit PEA3 function may prove ecacious or might complement those that seek to directly compromise HER2/Neu activity in tumors associated with increased HER2/neu gene expression.
Our data suggests a molecular model of breast tumorigenesis in which activation of PEA3 transcriptional activity by the HER2/Neu receptor tyrosine kinase contributes to the malignant phenotype of HER2/Neu-positive tumors. Each of the major facets of this model have been experimentally validated. We propose that an initiating event leads to increased HER2/Neu receptor tyrosine kinase activity resulting in upregulation of the transcriptional activity of PEA3. In turn transcriptionally-activated PEA3 stimulates the expression of its target genes, including the PEA3 and HER2/neu genes. The ability of HER2/Neu to increase PEA3 transcriptional activity and of PEA3 to transactivate HER2/neu expression assures that both the HER2/Neu and PEA3 proteins will be maximally active in tumor cells. As long as the initiating signal is maintained, then upregulation of PEA3 target gene expression is sustained at an increased level de®ned by the activity or abundance of the next most rate-limiting component required for target gene expression. The initiating event likey results from genetic changes because the transformed or tumorigenic phenotype is permanent in nature. Ampli®cation of the HER2/neu gene itself could provide such an initiation event, but any other genetic alteration leading to increased expression of the HER2/neu gene or activity of the HER2/Neu protein could trigger this oncogenic pathway. Genetic events impinging on PEA3 may have similar consequences, but this is unproven.
We were unable to detect increased levels of endogenous HER2/Neu in COS cells after transfection with the PEA3 eector plasmid (Figure 6c compare lanes 1 and 2). This observation apparently contradicts our hypothesis suggesting that PEA3 regulates HER2/ neu transcription. However, because calcium phosphate was used as a facilitator of DNA uptake in these experiments only 5 ± 10% of the cells were transfected with the PEA3 eector plasmid. If PEA3 stimulated expression of the endogenous HER2/neu gene in this fraction of the cell population, then a 10 ± 20-fold increase in HER2/Neu protein in the transfected cells would have to have occurred to have been detected. An increase in HER2/Neu protein of this magnitude in the transfected cells would have resulted in a 2 ± 3-fold overall increase of the protein in the total cell population. We did not detect such an increase suggesting that either PEA3 did not aect expression of the endogenous HER2/Neu protein or that its aect was to increase the level of the protein by less than 10 ± 20-fold. We note that ectopic expression of PEA3 stimulated CAT synthesis from the cotransfected HER2/neu promoter-CAT reporter by a factor of *®vefold (Figure 6a lane 3 ). An eect of this magnitude on the endogenous HER2/neu gene in the 5 ± 10% of cells transfected with the PEA3 eector would not have caused a detectable change in the overall abundance of the HER2/Neu protein in the total cell population. It is also noteworthy that our model predicts that an increase in both the amount and activity of PEA3 is needed to assure high PEA3 target gene expression. Thus coexpression of PEA3 and constitutively-activated HER2/Neu in the same cells would be needed to maximally increase expression of endogenous PEA3 and HER2/Neu transcripts. We are currently attempting such experiments through the use of more ecient mediators of DNA uptake and RNase-protection assays using riboprobes that distinguish between exogenous and endogenous PEA3 and HER2/Neu transcripts.
The fact that increased levels of PEA3 transcripts were observed in 43% of HER2/Neu-negative breast tumor samples also is not inconsistent with our model. The overall level of transcriptionally-active PEA3 in HER2/Neu-negative tumors may be insucient to trigger HER2/neu gene expression. As noted above, we imagine that both increased PEA3 abundance and increased transcriptional activity of the overexpressed PEA3 is required to eect upregulation of the HER2/ neu gene. If the HER2/Neu tyrosine kinase is not active, as is the case in HER2/Neu-negative tumors, then the transcriptional activity of PEA3 likely may not be markedly elevated despite increased amounts of the PEA3 protein in these tumor cells. The availability of an assay to measure transcriptionally-active PEA3 in breast tumor samples should allow us to discern dierences in PEA3 activity between HER2/Neunegative and -positive samples.
The downstream target genes of PEA3 include several matrix metalloproteinases. Hence, increased PEA3 activity in HER2/Neu-overexpressing breast tumors may upregulate matrix metalloproteinase expression thus endowing the tumor cells with invasive and metastatic properties. It is noteworthy that PEA3 transcripts are increased in an equal proportion of HER2/Neu-positive non-metastatic and metastatic human breast tumors suggesting that if PEA3 upregulation is required for metastasis, it is not sucient for this process to occur. It will be important to learn whether those matrix metalloproteinases that are thought to be regulated by PEA3 are indeed overexpressed in HER2/ Neu positive, PEA3-overexpressing breast tumors, and to learn whether this property correlates with their metastatic potential. This knowledge will have important implications in the treatment of human breast cancer and other cancers characterized by increased HER2/Neu and PEA3 overexpression.
Materials and methods

Human breast tumors and in situ hybridization analyses
Paran-embedded normal and neoplastic breast tissues were surgically excised between 1987 and 1992 and collected as part of the core tissue banking functions of two federally funded programs (CA44768 and CA58207) in which HER2/Neu receptor status is routinely determined by immunohistochemistry along with prognostic scoring of invasive tumors for estrogen receptor status, S-phase fraction and nuclear grade. For this study, HER2/Neupositivity was prospectively de®ned as 55% of tumor cells showing membrane immunoreactivity to the HER2/Neu antibodies 4D5 or CB11 (3) with membrane intensity being equivalent to or greater than that of the reference HER2/ Neu-positive breast cancer cell line, MDA-MB-453.
Immunohistochemically-determined HER2/Neu status was also veri®ed by in situ hybridization with riboprobes (antisense and sense) labeled with digoxigenin-11-dUTP that had been generated by run-o transcription from a subcloned 130 bp human HER2/neu cDNA fragment. PEA3 DNA templates for in vitro transcription were derived by subcloning a unique 5' region of human PEA3 cDNA; this DNA was transcribed by T3 or T7 RNA polymerase in the presence of [ 35 S]UTP thereby generating sense and antisense riboprobes. Ets-2 riboprobes were similarly prepared after subcloning a comparable region from human Ets-2 cDNA. The mRNA integrity of all tissue sections was established by hybridization of antisense and, as a control, sense riboprobes transcribed from a recombinant plasmid bearing human glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Consecutive tissue sections from individual tumors were hybridized in duplicate with sense and antisense riboprobes corresponding to each of these four genes (HER2/neu, PEA3, Ets-2 and GAPDH).
Standard in situ hybridization methodology was employed on the ®xed, four micron tissue sections applied to poly-Llysine coated slides. Pre-hybridization preparations included paran removal and tissue hydration, proteinase K treatment, acetylation and dehydration. Overnight hybridization with riboprobes were performed in 50% formamide at 458C; this was followed by a post-hybridization wash at 588C, RNase-A treatment, dehydration, autoradiography (exposure to Amersham Hypercoat Emulsion LM1 for at least 7 days at 48C) and hematoxylin counterstaining. Samples were scored for PEA3, Ets-2 and GAPDH expression under both bright-®eld and dark-®eld examination and blinded with regard to tissue histology as determined by two independent pathologists. Overexpression of the ets genes (PEA3-positivity or Ets-2-positivity) was de®ned by 4twofold increased signal density from the antisense probe as compared to background signal from the sense probe over all epithelial components on duplicate slides. Overall prevalency of overexpression was determined for each sample group and statistical comparisons within and between sample groups were performed by 262 chi-square contingency tables.
Cell culture
COS cells were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with fetal bovine serum (FBS) (10%), penicillin (50 units/ml) and streptomycin (50 mg/ml) at 378C in a humidi®ed CO 2 atmosphere. Human breast cancer cell lines (MCF-7) and MDA-MB-453) were cultured as previously described Scott et al., 1994) .
DNaseI footprinting
DNaseI footprinting was performed using a gel-puri®ed, 32 P-end-labeled mPEA3 promoter fragment (7355 to +1 bp) incubated with nuclear extracts from low PEA3-expressing MCF-7 and PEA3-overexpressing MDA-MB-453 cells as well as with puri®ed, recombinant hPEA3 protein (Scott et al., 1994) . Reaction mixtures (10 ml) contained nuclear extract or recombinant protein, 10 fmoles of 32 P-labeled DNA and 506non-speci®c DNA competitor in binding buer (11 mM CaCl 2 and 22 mM MgCl 2 ). Protein was added last and binding allowed to proceed for 15 min at room temperature before the addition of sucient DNaseI to produce partial cleavage products (usually about 1 min digestion). Digestion was arrested with the addition of a stopping solution (200 mM sodium chloride, 30 mM EDTA, 1% SDS, 5 mg yeast tRNA); the DNA was extracted with phenol and chloroform, and ethanol precipitated. Thereafter, the DNA was resuspended in formamide-containing buer (97% formamide, 15 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol), heated (908C63 min) and loaded onto a 6% polyacrylamide-8 M urea sequencing gel. After electrophoresis the DNA fragments were identi®ed by autoradiography.
Recombinant plasmids
The PEA3 reporter plasmid comprises a synthetic TATA box corresponding to that of the adenovirus two major late promoter, and four tandem head-to-tail copies of the PEA3 binding site (shown in bold) (5'-GATCCAGGAAGTGAC-3') from the polyomavirus enhancer juxtaposed upstream of the CAT gene and accompanying SV40 polyadenylation signals (Xin et al., 1992) . The mPEA3 promoter (7156 to +676) was cloned upstream of the luciferase gene in the pGL3-basic vector (Clonetech) (Barrett and Hassell, in preparation). The CAT reporter plasmids bearing the 500 bp human HER2/neu promoter fragment and its mutant counterpart lacking a functional PEA3 binding site have been described previously (Scott et al., 1994) . The PEA3 eector contains a cDNA encoding full-length mPEA3 positioned downstream of the RSV promoter in the pRc/RSV expression vector (Invitrogen) and was constructed as described (O'Hagan et al., 1996) . Normal (wt) HER2/neu and its constitutively-activated counterpart were cloned in the pJ4 omega expression vector (Morgenstern and Land, 1990) .
Transfections and CAT assays
COS cells were transfected with 1.5 mg of the reporter plasmids and 3.0 mg of the eector plasmids unless otherwise indicated. The total DNA concentration was adjusted to 21 mg per 100 mm Petri dish with herring sperm DNA where required. The cells were transfected by the calcium phosphate procedure for 20 h and then allowed to recover for 10 h in DMEM supplemented with 10% FBS. Thereafter the cells were starved of serum for 40 h before they were collected, suspended in 250 mM Tris-HCl, pH 7.5, and lysed by freeze-thaw for analysis of CAT activity (O'Hagan et al., 1996) . For luciferase assays the cells were lysed and the cell extracts analysed using buers and reagents provided by Promega. Generally, between 5 ± 10% of the cells were transfected using this procedure.
Protein analyses
To assay the amount of PEA3 or HER2/Neu protein expressed after transfection, the cells were collected and lysed in ice cold buer containing 1% NP40, 50 mM TrisHCl, pH 7.4, 5 mM EDTA, 400 mM NaCl, 2 mg/ml PMSF, 1 mg/ml each of leupeptin, pepstatin and aprotinin. Samples (50 mg of total protein/sample) were resolved by electrophoresis in 9% SDS ± PAGE gels and transferred to PVDF membranes by electroblotting. PEA3 was detected using the mouse MP16 monoclonal antibody, whereas HER2/Neu was detected using Ab-3 from Oncogene Sciences. Immunoblots were developed using the enhanced chemiluminescence system (Boehringer Mannheim).
